Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 54, Issue 6

Issues

Free light chains and heavy/light chains in monitoring POEMS patients

Sara Altinier
  • Corresponding author
  • Department of Laboratory Medicine, University-Hospital of Padua, Via Giustiniani 2, 35128 Padova, Italy, Phone: +39 049 821 8708, Fax: +39 049 821 8489
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Kozeta Proko / Martina Zaninotto / Daniela Ciubotaru / Mara Seguso / Mariacristina Varagnolo / Federica Lessi / Chiara Briani / Fausto Adami / Mario PlebaniORCID iD: http://orcid.org/0000-0002-0270-1711
Published Online: 2016-04-12 | DOI: https://doi.org/10.1515/cclm-2015-0910

Abstract

Background: POEMS syndrome is defined by Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy and Skin changes. The vascular endothelial growth factor (VEGF) appears to play a key role in the pathogenesis of the syndrome, and its concentrations are deemed to correlate to disease activity. The aim of the present study was to verify whether other biochemical markers including serum free light chains (FLC) and heavy/light chains (HLC) would be of value in monitoring POEMS patients.

Methods: Fifty-three serum samples were collected from seven POEMS patients at diagnosis and during a follow-up period (range 14–56 months). VEGF was measured using an ELISA method, while FLC and HLC concentrations were measured using Binding Site reagents on a BNII (Siemens) nephelometer.

Results: At diagnosis all patients presented high VEGF concentrations, while the κ/λFLC ratio (FLCr) was within the reference range. Four patients had abnormal HLC, HLCκ/HLCλ (HLCr) and FLC values. The relationship between the trend of VEGF and both HLC and FLC during the follow-up was analysed by means of Cohen’s κ coefficient. VEGF and HLC values displayed a significant κ-Cohen (0.537, p=0.002) in all chemotherapy-responder patients while in non-responders it did not. Conversely, in both responders and non-responders, VEGF and FLC values did not attain a significance on κ-Cohen analysis. In three out of four responders HLCr values increased, thus reflecting an improved clinical condition.

Conclusions: The findings made in the present study indicate that HLC, either as intact immunoglobulin or as HLCr, may provide useful information, particularly in identifying responders and confirm that the role of FLC is unreliable in monitoring patients with POEMS syndrome.

Keywords: free light chains; heavy/light chains; monoclonal gammopathy; POEMS syndrome; vascular endothelial growth factor

References

  • 1.

    Dispenzieri A, Kyle RA, Lacy MQ, Rajkumar SV, Therneau TM, Larson DR, et al. POEMS syndrome: definitions and long-term outcome. Blood 2003;101:2496–506.Google Scholar

  • 2.

    Dispenzieri A. POEMS syndrome: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:214–23.Google Scholar

  • 3.

    Scarlato M, Previtali SC, Carpo M, Pareyson D, Briani C, Del Bo R, et al. Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. Brain 2005;128:1911–20.Google Scholar

  • 4.

    Soubrier M, Dubost JJ, Serre AF, Ristori JM, Sauvezie B, Cathebras P, et al. Growth factors in POEMS syndrome: evidence for a marked increase in circulating vascular endothelial growth factor. Arthritis Rheum 1997;40:786–7.Google Scholar

  • 5.

    D’Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood 2011;118:4663–5.Web of ScienceGoogle Scholar

  • 6.

    Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673–80.Google Scholar

  • 7.

    Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215–24.Web of ScienceGoogle Scholar

  • 8.

    Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin κ/λ ratios. Clin Chem 2009;55:1646–55.Web of ScienceGoogle Scholar

  • 9.

    Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, et al. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 2013;27:208–12.Google Scholar

  • 10.

    Koulieris E, Panayiotidis P, Harding SJ, Kafasi N, Maltezas D, Bartzis V, et al. Ratio of involved/uninvolved immunoglobulin quantification by Hevylite™ assay: clinical and prognostic impact in multiple myeloma. Exp Hematol Oncol 2012;23:1–9.Google Scholar

  • 11.

    Katzmann JA, Willrich MA, Kohlhagen MC, Kyle RA, Murray DL, Snyder MR, et al. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. Clin Chem 2015;61:360–7.Web of ScienceGoogle Scholar

  • 12.

    D’Souza A, Lacy M, Gertz M, Kumar S, Buadi F, Hayman S et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma): a single-center experience. Blood 2012;120:56–62.Google Scholar

  • 13.

    Altinier S, Seguso M, Zaninotto M, Varagnolo M, Adami F, Angeli P, et al. Serum free light chain reference values: a critical approach. Clin Biochem 2013;46:691–3.Web of ScienceGoogle Scholar

  • 14.

    Ludwig H, Milosavljevic D, Zojer N, Faint JM, Bradwell AR, Hübl W, et al. Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients. Leukemia 2013;27:213–9.Google Scholar

  • 15.

    Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, et al. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer 2014;120:3952–7.Google Scholar

  • 16.

    Stankowski-Drengler T, Gertz MA, Katzmann JA, Lacy MQ, Kumar S, Leung N, et al. Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome. Am J Hematol 2010;85:431–4.Web of ScienceGoogle Scholar

  • 17.

    Wang C, Su W, Zhang W, Di Q, Duan MH, Ji W, et al. Serum immunoglobulin free light chain and heavy/light chain measurements in POEMS syndrome. Ann Hematol 2014;93:1201–6.Web of ScienceGoogle Scholar

  • 18.

    Wang C, Su W, Cai QQ, Cai H, Ji W, Di Q, et al. Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome. Eur J Haematol 2015. doi:.CrossrefGoogle Scholar

About the article

Received: 2015-09-18

Accepted: 2016-03-02

Published Online: 2016-04-12

Published in Print: 2016-06-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 54, Issue 6, Pages 1065–1071, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2015-0910.

Export Citation

©2016 by De Gruyter.Get Permission

Comments (0)

Please log in or register to comment.
Log in